Asia Pacific Rare Biomarkers Specimen Collection And Stabilization Market Size & Outlook

The rare biomarkers specimen collection and stabilization market in Asia Pacific is expected to reach a projected revenue of US$ 12,677.4 million by 2030. A compound annual growth rate of 13.3% is expected of Asia Pacific rare biomarkers specimen collection and stabilization market from 2024 to 2030.
Revenue, 2023 (US$M)
$5,278.4
Forecast, 2030 (US$M)
$12,677.4
CAGR, 2024 - 2030
13.3%
Report Coverage
Asia Pacific

Asia Pacific rare biomarkers specimen collection and stabilization market, 2018-2030 (US$M)

Asia

Asia Pacific rare biomarkers specimen collection and stabilization market highlights

  • The Asia Pacific rare biomarkers specimen collection and stabilization market generated a revenue of USD 5,278.4 million in 2023.
  • The market is expected to grow at a CAGR of 13.3% from 2024 to 2030.
  • In terms of segment, circulating cell free dna (ccfdna) was the largest revenue generating biomarker in 2023.
  • Circulating Cell Free DNA (ccfDNA) is the most lucrative biomarker segment registering the fastest growth during the forecast period.


Asia Pacific data book summary

Market revenue in 2023USD 5,278.4 million
Market revenue in 2030USD 12,677.4 million
Growth rate13.3% (CAGR from 2023 to 2030)
Largest segmentCirculating cell free dna (ccfdna)
Fastest growing segmentCirculating Cell Free DNA (ccfDNA)
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCirculating Cell Free DNA (ccfDNA)
Key market players worldwideQiagen NV, Charles River Laboratories International Inc, Roche Holding AG ADR, Thermo Fisher Scientific Inc, Eurofins Scientific SE, PerkinElmer, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Merck KGaA, Siemens Healthineers AG ADR


Other key industry trends

  • In terms of revenue, Asia Pacific region accounted for 14.0% of the global rare biomarkers specimen collection and stabilization market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 12,677.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Rare Biomarkers Specimen Collection And Stabilization Market Scope

Rare biomarkers specimen collection and stabilization market segmentation & scope
Circulating Cell Free DNA (ccfDNA)
Circulating Tumor Cells
Exosomes/Extracellular Vesicles
Oncology (Research and Diagnostics)
Research
Diagnostics
Screening
Treatment Monitoring
Transplant rejection (Research)
Transcriptomics (Research)
Cardiovascular diseases (Research)
Pharmacogenomics (Research)
NIPT (Research)
Population screening (Research)
Other applications (Research)
Circulating Cell Free RNA (ccfRNA) / miR
Oncology (Research and Diagnostics)
Research
Diagnostics
Transplant rejection (Research)
Transcriptomics (Research)
Cardiovascular diseases (Research)
Pharmacogenomics (Research)
NIPT (Research)
Population screening (Research)
Other applications (Research)
End Use
Research
Research Labs/CROs
Academic Institutes
Diagnostics
Laboratories
Hospitals
Prenatal Clinics
Countries
U.S.
Canada
Germany
UK
France
Spain
Italy
Netherlands
China
India
Japan
South Korea
Australia
Singapore
Brazil
South Africa

Rare Biomarkers Specimen Collection And Stabilization Market Companies

Name Profile # Employees HQ Website

Asia Pacific rare biomarkers specimen collection and stabilization market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare biomarkers specimen collection and stabilization market will help companies and investors design strategic landscapes.


Circulating cell free dna (ccfdna) was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Asia Pacific rare biomarkers specimen collection and stabilization market based on circulating cell free dna (ccfdna) covering the revenue growth of each sub-segment from 2018 to 2030.


The ongoing conferences and seminars for raising awareness about the role of rare biomarkers in disease management, among Asian population including patients, healthcare personnel, and research entities, are driving the revenue share of this regional market. 

For instance, in September 2019, a conference titled Circulating Biomarkers, Exosomes & Liquid Biopsy Asia 2019 was conducted in Seoul, Korea. In March 2019, Precipio, Inc., a specialty diagnostics company, announced the continuous purchase for its ICP liquid biopsy enrichment solution from both repeat and new customers in Japan. 

Recently, the Tokyo-based Kyorin University Hospital placed its third order for ICP assay. This reflects the expanding liquid biopsy space in this region.

Reasons to subscribe to Asia Pacific rare biomarkers specimen collection and stabilization market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Asia Pacific rare biomarkers specimen collection and stabilization market databook

  • Our clientele includes a mix of rare biomarkers specimen collection and stabilization market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific rare biomarkers specimen collection and stabilization market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific rare biomarkers specimen collection and stabilization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Asia Pacific rare biomarkers specimen collection and stabilization market

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more